Profile data is unavailable for this security.
About the company
Virios Therapeutics, Inc. is a development-stage biotechnology company. The Company is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia (FM) and Long-COVID (LC). Its lead candidate, IMC-1, is a novel, proprietary, fixed dose combination of famciclovir and celecoxib. IMC-1 represents a novel combination, dual mechanism antiviral therapy designed to synergistically suppress herpes virus activation and replication, with the end goal of reducing viral mediated disease burden. IMC-2 is a combination of valacyclovir and celecoxib that is believed to have specific activity against Epstein-Barr virus (herpesvirus HHV-4), as well as other herpesviruses. IMC-1 and IMC-2 combine two specific mechanisms of action purposely designed to inhibit herpesvirus activation and replication, thereby converting activated herpesvirus back to dormancy and/or by keeping the herpesvirus in a latent or dormant state.
- Revenue in USD (TTM)0.00
- Net income in USD-5.07m
- Incorporated2020
- Employees4.00
- LocationVirios Therapeutics Inc44 Milton AvenueALPHARETTA 30009United StatesUSA
- Websitehttps://www.virios.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Burzynski Research Institute Inc | 0.00 | -1.34m | 5.83m | 2.00 | -- | -- | -- | -- | -0.0102 | -0.0102 | 0.00 | -0.0002 | 0.00 | -- | -- | -- | -62,992.45 | -15,304.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -45.74 | -- | -- | -- |
NuCana PLC (ADR) | 0.00 | -33.89m | 5.84m | 25.00 | -- | 0.4868 | -- | -- | -302.91 | -302.91 | 0.00 | 5.67 | 0.00 | -- | -- | 0.00 | -72.34 | -41.01 | -125.17 | -48.07 | -- | -- | -- | -- | -- | -- | 0.0324 | -- | -- | -- | 13.71 | -- | -21.70 | -- |
Ainos Inc | 93.68k | -14.56m | 5.91m | 46.00 | -- | 0.2547 | -- | 63.06 | -3.27 | -3.27 | 0.0206 | 3.69 | 0.0028 | 0.8133 | 1.62 | 2,036.52 | -43.83 | -36.36 | -48.64 | -58.33 | -222.11 | 36.82 | -15,547.49 | -813.63 | 0.2847 | -75.23 | 0.2003 | -- | -96.53 | 9.46 | 1.69 | -- | 66.44 | -- |
Cyclerion Therapeutics Inc | 0.00 | -10.95m | 6.11m | 1.00 | -- | 0.568 | -- | -- | -4.38 | 0.2904 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -95.95 | -72.70 | -158.12 | -86.96 | -- | -- | -- | -2,565.62 | -- | -- | 0.00 | -- | -100.00 | -- | 30.98 | -- | -- | -- |
Tenax Therapeutics Inc | 0.00 | -10.10m | 6.23m | 5.00 | -- | 0.501 | -- | -- | -24.52 | -24.52 | 0.00 | 6.35 | 0.00 | -- | -- | 0.00 | -67.96 | -199.16 | -75.66 | -285.64 | -- | -- | -- | -- | -- | -105.12 | 0.0322 | -- | -- | -- | 30.21 | -- | -- | -- |
Kazia Therapeutics Ltd (ADR) | 15.12k | -13.72m | 6.27m | 12.00 | -- | 0.5936 | -- | 414.27 | -0.8322 | -0.8322 | 0.0008 | 0.3543 | 0.0007 | -- | 73.97 | -- | -63.98 | -46.35 | -82.39 | -54.75 | -- | -- | -90,714.45 | -497.17 | -- | -- | 0.1297 | -- | 979.43 | -28.31 | 18.19 | -- | -- | -- |
Enzolytics Inc | 0.00 | -119.19k | 6.38m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
ENDRA Life Sciences Inc | 0.00 | -9.89m | 6.39m | 21.00 | -- | 0.2686 | -- | -- | -1.26 | -1.26 | 0.00 | 0.3388 | 0.00 | -- | -- | 0.00 | -168.89 | -132.00 | -228.29 | -157.28 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 23.67 | -- | -19.46 | -- |
Virios Therapeutics Inc | 0.00 | -5.07m | 6.66m | 4.00 | -- | -- | -- | -- | -0.2673 | -0.2673 | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 56.76 | -- | -- | -- |
Kineta Inc | 5.16m | -17.89m | 6.88m | 11.00 | -- | -- | -- | 1.33 | -1.55 | -1.55 | 0.4673 | -0.564 | 0.6667 | -- | -- | 469,181.80 | -230.51 | -66.16 | -- | -86.61 | -- | -- | -345.77 | -854.74 | -- | -- | -- | -- | 178.65 | 13.89 | 77.76 | -- | -- | -- |
Viaderma Inc | 17.80m | 2.31m | 6.91m | 75.00 | 0.0003 | 0.00002 | 1.28 | 0.3881 | 16.84 | 16.84 | 129.62 | 255.59 | 0.4126 | 24.69 | 1.21 | 237,331.30 | 5.36 | -- | 6.53 | -- | 28.90 | -- | 12.99 | -- | 2.07 | 5.66 | 0.1718 | -- | -29.15 | -- | -40.70 | -- | -- | -- |
Marizyme Inc | 549.70k | -69.02m | 7.13m | 11.00 | -- | -- | -- | 12.97 | -1.42 | -1.42 | 0.0081 | -0.0822 | 0.0184 | 1.65 | 14.06 | 49,972.73 | -230.68 | -59.02 | -531.63 | -64.47 | 71.17 | 70.38 | -12,555.69 | -9,435.92 | 0.0279 | -0.5837 | 1.92 | -- | 176.59 | 99.98 | -71.22 | -- | -- | -- |
Cell MedX Corp | 70.00 | -96.91k | 7.13m | 0.00 | -- | -- | -- | 101,909.60 | -0.0029 | -0.0029 | 0.00 | -0.0024 | 0.0015 | -- | -- | -- | -202.28 | -792.55 | -- | -- | -685.71 | -- | -138,442.90 | -3,681.84 | -- | -3.17 | -- | -- | -54.53 | -- | 29.01 | -- | -- | -- |
Chromocell Therapeutics Corp | 0.00 | -8.98m | 7.21m | 4.00 | -- | 6.38 | -- | -- | -1.66 | -1.66 | 0.00 | 0.196 | 0.00 | -- | -- | 0.00 | -440.01 | -- | -- | -- | -- | -- | -- | -- | -- | -7.20 | 0.00 | -- | -- | -- | -200.20 | -- | -- | -- |
Geovax Labs Inc | 0.00 | -27.78m | 7.33m | 17.00 | -- | 123.33 | -- | -- | -14.42 | -14.42 | 0.00 | 0.0235 | 0.00 | -- | -- | 0.00 | -180.60 | -108.34 | -242.41 | -147.24 | -- | -- | -- | -1,842.93 | -- | -- | 0.00 | -- | -100.00 | -- | -85.20 | -- | -- | -- |
Galera Therapeutics Inc | 0.00 | -45.75m | 7.51m | 7.00 | -- | -- | -- | -- | -0.9971 | -0.9971 | 0.00 | -2.48 | 0.00 | -- | -- | 0.00 | -115.30 | -83.69 | -142.79 | -97.54 | -- | -- | -- | -- | -- | -6.49 | 9.23 | -- | -- | -- | 5.05 | -- | -29.84 | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 31 Mar 2024 | 208.88k | 0.75% |
Geode Capital Management LLCas of 31 Mar 2024 | 174.47k | 0.63% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 52.83k | 0.19% |
McCollum Christoferson Group LLCas of 31 Mar 2024 | 42.00k | 0.15% |
Raymond James & Associates, Inc. (Invt Mgmt)as of 31 Mar 2024 | 30.00k | 0.11% |
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 24.04k | 0.09% |
G1 Execution Services LLCas of 31 Mar 2024 | 23.36k | 0.08% |
Regions Investment Management, Inc.as of 31 Mar 2024 | 20.07k | 0.07% |
The Northwestern Mutual Life Insurance Co. (Invt Port)as of 31 Mar 2024 | 19.06k | 0.07% |
Jane Street Capital LLCas of 31 Mar 2024 | 17.00k | 0.06% |